No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)

- Prevention of atherothrombotic events in patients after myocardial infarction (with prescription from several days to 35 days), ischemic stroke (with prescription from 7 days to 6 months) or having a diagnosed occlusive peripheral artery disease.
- Prevention of atherothrombotic events (in combination with acetylsalicylic acid) in patients with acute coronary syndrome:
- without ST segment elevation (unstable angina or myocardial infarction without a Q wave), including patients who underwent stenting for percutaneous coronary intervention;
- With the rise of the ST segment (acute myocardial infarction) with drug treatment and the possibility of thrombolysis.

- Increased sensitivity to clopidogrel or any of the excipients of the drug.
- Severe liver failure.
- Acute bleeding, such as bleeding from a peptic ulcer or intracranial hemorrhage.
-Rare hereditary lactose intolerance, lactase deficiency and glucose-galactose malabsorption.
Pregnancy and lactation (see "Pregnancy and breastfeeding").
-Child age up to 18 years (safety and efficacy have not been established).

- Moderate hepatic impairment, in which a predisposition to bleeding is possible (limited clinical experience of use).
- Renal failure (limited clinical experience).
- Trauma, surgical interventions (see. "Special Instructions").
- Diseases in which there is a predisposition to the development of bleeding (especially gastrointestinal or intraocular).
- Simultaneous administration of nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors (COX-2).
- The simultaneous appointment of Warfarin, Heparin, glycoprotein IIb / IIIa inhibitors.
- In patients with a genetically determined decrease in the function of the isoenzyme CYP2C19 in recommended doses (there are literature data indicating that patients with a genetically determined decrease in the function of the isoenzyme CYP2C19 are exposed to a lower systemic exposure to the active metabolite of clopidogrel and have a less pronounced effect of the drug, in addition, they may there is a higher incidence of cardiovascular complications after myocardial infarction compared with patients with normal function of the isoenzyme CYP2C19).
Use during pregnancy and during breastfeeding

As a precaution, taking clopidogrel during pregnancy is not recommended due to the lack of clinical data on its use by pregnant women, although animal studies did not reveal any direct or indirect adverse effects on the course of pregnancy, fetal development, childbirth and postnatal development.Breastfeeding in the case of treatment with clopidogrel should be discontinued, since in studies in rats it has been shown that clopidogrel and / or its metabolites are excreted into breast milk. Whether clopidogrel penetrates human breast milk is unknown.

Adults and elderly patients with normal activity of the isoenzyme CYP2C19

Clopidogrel-SZ should be taken orally, regardless of the meal.
Myocardial infarction, ischemic stroke and diagnosed occlusive peripheral artery disease

The drug is taken at 75 mg once a day.
In patients with myocardial infarction (MI), treatment can be started from the first days to 35 days of MI, and in patients with ischemic stroke (AI), from 7 days to 6 months after AI.
Acute coronary syndrome without ST segment elevation (unstable stenocardia, myocardial infarction without Q wave)

Treatment with Klopidogrel-SZ should be started with a single dose of a loading dose of 300 mg and then continued with a dose of 75 mg once a day (in combination with Acetylsalicylic acid as an antiplatelet agent at doses of 75-325 mg per day). Since the use of higher doses of acetylsalicylic acid is associated with an increased risk of bleeding, the dose of acetylsalicylic acid recommended for this indication should not exceed 100 mg. The maximum therapeutic effect is observed by the third month of treatment. The course of treatment up to 1 year.
Acute coronary syndrome with ST segment elevation (acute myocardial infarction with ST segment elevation)

Clopidogrel-SZ is administered once at a dose of 75 mg once a day with an initial single dose of a loading dose in combination with acetylsalicylic acid as an antiplatelet agent and thrombolytic (or without thrombolytic). Combination therapy is started as soon as possible after the onset of symptoms and continues for at least four weeks. In patients older than 75 years, treatment with Klopidogrel-SZ should begin without taking its loading dose.
Patients with a genetically determined decrease in the function of the isoenzyme CYP2C19

The weakening of metabolism using the isoenzyme CYP2C19 can lead to a decrease in the antiplatelet effect of clopidogrel. The optimal dosing regimen for patients with a weakened metabolism using the isoenzyme CYP2C19 has not yet been established.
Patients with impaired renal function

After repeated administration of the drug Klopidogrel-SZ at a dose of 75 mg / day in patients with severe kidney damage (creatinine clearance from 5 to 15 ml / min), the inhibition of ADP-induced platelet aggregation (25%) was lower compared to that in healthy volunteers, however, the lengthening of the bleeding time was similar to that of healthy volunteers who received Klopidogrel-SZ at a dose of 75 mg per day. In addition, all patients had good tolerability.
Patients with impaired liver function

After daily administration of clopidogrel SZ at a dose of 75 mg daily for 10 days in patients with severe liver damage, the inhibition of ADP-induced platelet aggregation was similar to that in healthy volunteers. The average bleeding time was also comparable in both groups.
Patients of different ethnicity

The prevalence of CYP2C19 isoenzyme gene alleles, which are responsible for the intermediate and reduced metabolism of clopidogrel to its active metabolite, differs among members of different ethnic groups (see the Pharmacogenetics section). Only limited data are available for representatives of the Mongoloid race to assess the effect of the CYP2C19 isoenzyme genotype on the clinical outcomes.

Classification of the incidence of side effects (WHO):
often more than 1/100 and less than 1/10,
infrequently - more than 1/1000 and less than 1/100,
rarely more than 1/10000 and less than 1/1000,
very rarely - less than 1/10000).
From the central and peripheral nervous system:

infrequently - headache, dizziness and paresthesias:
rarely - vertigo;
very rarely - a violation of taste.
From the digestive system:

often - diarrhea, abdominal pain, dyspepsia ;
infrequently - gastric and duodenal ulcers, gastritis, vomiting, nausea, constipation, flatulence;
very rarely - pancreatitis, colitis (including ulcerative or lymphocytic colitis), stomatitis.
Hemostatic disorders:

infrequently - lengthening bleeding time.
Hematopoietic disorders:

infrequently - thrombocytopenia, leukopenia, neutropenia and eosinophilia,
very rarely - thrombocytopenic thrombo-hemolytic purpura, severe thrombocytopenia (platelet count ≤ 30x109 / l), agranulocytosis, granulocytopenia, aplastic anemia (pancytopenia), anemia.
Violations of the skin and subcutaneous tissues:

infrequently - skin rash and itching;
very rarely - angioedema, urticaria, erythematous rash (associated with clopidogrel or acetylsalicylic acid);
very rarely - bullous dermatitis (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), eczema and lichen planus.
Violations by the immune system:

very rarely - anaphylactoid reactions, serum sickness.
Mental disorders:

very rarely - confusion, hallucinations.
Violations of the vascular system:

very rarely - vasculitis, marked reduction in blood pressure (BP), intracranial hemorrhage, eye hemorrhages (conjunctival, in the tissue and retina), hematoma, nosebleeds, bleeding from the respiratory tract, Gastrointestinal bleeding, retroperitoneal hemorrhage, death in muscles and joints, hematuria, etc.
Respiratory disorders:

very rarely - bronchospasm, interstitial pneumonitis.
Violations of the hepato-biliary system:

very rarely - acute liver failure, hepatitis.
Violations of the musculoskeletal system:

very rarely - arthralgia, arthritis, myalgia.
Kidney and urinary tract disorders:

very rarely - glomerulonephritis.
General violations:

very rarely - fever.
Changes in laboratory parameters:

very rarely - a change in liver function tests, an increase in serum creatinine concentration.

 prolongation of bleeding time with subsequent complications in the form of bleeding.
 stop bleeding, platelet mass transfusion. The antidote is unknown.

simultaneous use with clopidorrel can increase the intensity of bleeding, so the use of this combination is not recommended.
IIb / IIIa receptor blockers:
appointment of blockers IIb / IIIa receptors, together with clopidogrel, requires caution in patients who have an increased risk of bleeding (for injuries and surgical interventions or other pathological conditions) (see section "Special Instructions").
Acetylsalicylic acid:
acetylsalicylic acid does not alter the effect of clopidogrel, which inhibits ADP-induced platelet aggregation, but clopidogrel potentiates the effect of acetylsalicylic acid on collagen-induced platelet aggregation. However, the simultaneous use of acetylsalicylic acid as an antipyretic with clopidogrel, 500 mg 2 times a day for 1 day did not cause a significant increase in the bleeding time caused by clopidogrel administration.Between clopidogrel and acetylsalicylic acid pharmacodynamic interaction is possible, which leads to an increased risk of bleeding. Therefore, with their simultaneous use, care should be taken, although in clinical studies, patients received combination therapy with clopidogrel and acetylsalicylic acid for up to one year.
According to a clinical study conducted with the participation of healthy volunteers, taking clopidogrel did not require a change in the dose of heparin and its anticoagulant effect did not change. The simultaneous use of heparin did not alter the antiplatelet effect of clopidogrel. Between clopidogrel and heparin, pharmacodynamic interaction is possible, which may increase the risk of bleeding, therefore the simultaneous use of these drugs requires caution.
the safety of simultaneous use of clopidogrel, fibrin-specific or fibrin-specific thrombolytic drugs and heparin was studied in patients with acute myocardial infarction. Frequently clinically significant bleeding was similar to that observed in the case of simultaneous use of thrombolytic agents and heparin with acetylsalicylic acid.
Non-steroidal anti-inflammatory drugs (NSAIDs):
in a clinical study conducted with the participation of healthy volunteers, the simultaneous use of clopidogrel and Naproxen increased latent blood loss through the gastrointestinal tract.However, due to the lack of research on the interaction of clopidogrel with other NSAIDs, it is currently not known whether there is an increased risk of gastrointestinal bleeding when taking clopidogrel along with other NSAIDs. Therefore, the appointment of NSAIDs, including selective inhibitors of COX-2, in combination with clopidogrel should be carried out with caution (see section "Special instructions").
Other combination therapy

Since clopidogrel is metabolized to the formation of its active metabolite partially using the isoenzyme CYP2C19, the use of drugs inhibiting this system can lead to a decrease in the level of the active metabolite of clopidogrel and a decrease in its clinical efficacy. Simultaneous administration of drugs inhibiting the isoenzyme СYP2C19 (for example, omeprazole) is not recommended.
A number of clinical studies were conducted with clopidogrel and other concomitantly prescribed drugs in order to study possible pharmacodynamic and pharmacokinetic interactions, which showed that:
- when using clopidogrel together with Atenolol, Nifedipine or with both drugs at the same time, no clinically significant pharmacodynamic interaction was observed;
- simultaneous use of phenobarbital, cimetidine and estrogen had no significant effect on clopidogrel pharmacodynamics;
- pharmacokinetic indices of Digoxin and theophylline did not change when they were applied simultaneously with clopidogrel.
- antiacid means did not reduce the absorption of clopidogrel.
- Phenytoin and tolbutamide can be safely applied simultaneously with clopidogrel, despite the fact that the data obtained during studies with human liver microsomes indicate that the carboxyl metabolite of clopidogrel may inhibit the activity of the CYP2C9 isoenzyme, which can lead to an increase in plasma concentrations drugs (phenytoin, tolbutamide, and some NSAIDs) that are metabolized by the isoenzyme CYP2C9.
- angiotensin-converting enzyme (ACE) inhibitors, diuretics, beta-blockers, slow Calcium channel blockers, hypoglycemic agents (including insulin), lipid-lowering drugs, antiepileptic drugs, hormone replacement therapy and GPIIb / IIIa receptors blockers : In clinical studies, no clinically relevant undesirable interactions were detected.

When treating Klopidogrel-SZ, especially during the first weeks of treatment and / or after invasive cardiac procedures / surgery, it is necessary to carefully monitor patients to exclude signs of bleeding, including hidden ones.
Due to the risk of bleeding and hematological undesirable effects (see the “Side effect” section) if clinical symptoms that are suspicious of bleeding occur during the treatment,An urgent clinical blood test should be performed, the activated partial thromboplastin time (APTT), the number of platelets, the indicators of the functional activity of platelets and other necessary studies should be determined.
Clopidogrel-SZ, as well as other antiplatelet drugs, should be used with caution in patients with an increased risk of bleeding associated with injuries, surgical interventions or other pathological conditions, as well as in patients receiving acetylsalicylic acid, nonsteroidal anti-inflammatory drugs, including COX-2 inhibitors, heparin or glycoprotein IIb / IIIa inhibitors.
The combined use of clopidogrel with warfarin can increase the intensity of bleeding (see "Interaction with other drugs"), therefore, with the exception of special rare clinical situations (such as the presence of a floating thrombus in the left ventricle, stenting in patients with atrial fibrillation), the use of clopidogrel and warfarin is not recommended.
If the patient has a planned surgical intervention, and there is no need for an antiplatelet effect, then 7 days before the operation, the use of the drug Klopidogrel-SZ should be stopped.
Clopidogrel prolongs bleeding time and should be used with caution in patients with diseases that predispose to the development of bleeding (especially gastrointestinal and intraocular).
Patients should be warned that when taking the drug Klopidogrel-SZ (alone or in combination with acetylsalicylic acid) it may take longer to stop the bleeding, and that if they have unusual (by localization or duration) bleeding they should report this to their health care provider. Before any forthcoming operation and before the start of taking any new drug, patients should inform the doctor (including the dentist) about taking the drug Klopidogrel-SZ.
Very rarely, after use of the drug Klopidogrel-SZ (sometimes even briefly), there have been cases of thrombocytopenic thrombohemolytic purpura (THP), which is characterized by thrombocytopenia and microangiopathic hemolytic anemia, accompanied by neurological disorders, impaired kidney function and fever. TBD is a potentially life-threatening condition that requires immediate treatment, including plasmapheresis.
During the period of treatment it is necessary to control the functional activity of the liver. For severe violations of liver function, you should remember the risk of hemorrhagic diathesis. The use of Klopidogrel-SZ is not recommended for acute stroke with a prescription of less than 7 days (as there are no data on its use in this condition). Clopidogrel-SZ should not be taken in patients with rare hereditary galactose intolerance, lactase deficiency and glucose-galactose malabsorption syndrome ( see “Composition”).

Klopidogrel-SZ does not have a significant impact on the ability to drive vehicles or work with machinery.

Tablets, film coated, 75 mg. On 10, 14 or 30 tablets in a blister strip packaging. 30 tablets in a polymer can or in a polymer bottle. 3, 6 blister packs of 10 tablets, 1, 2, 4 blister packs of 14 tablets, 1, 2, 3 blister packs of 30 tablets, can or bottle with application instructions in a carton box.

In dry, the dark place at a temperature of no higher than 25aboutWITH. Keep out of the reach of children.


43 Items